In Memory of Robert Rapp

The entire staff at the Multiple Sclerosis Association of America (MSAA), as well as many of MSAA’s corporate partners, are mourning the loss of our former Chief Operating Officer and treasured colleague, Robert “Bob” Rapp. Following a successful career in education and public service, Bob joined the staff of MSAA as Director of Services in […]

Read News Article

FDA Accepts Application for Cladribine Tablets

EMD Serono, Inc. announced today that the United States Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Cladribine Tablets (an oral formulation of cladribine), an investigational treatment for relapsing forms of MS. Accepted by the European Commission in August 2017 and by Canada in December 2017, Cladribine is currently approved […]

Read News Article

MSAA’s Publications Honored by the 30th Annual APEX Awards

The Multiple Sclerosis Association of America (MSAA) is proud to announce that we have received two awards from the 30th Annual APEX Awards for Publication Excellence! These were given for MSAA’s informative booklet, Understanding Progression in MS, and for the Summer/Fall 2017 edition of The Motivator. MSAA was presented with an Award of Excellence in […]

Read News Article

Research Highlights from the AAN and CMSC 2018 Annual Meetings

In this Article Disease-Modifying Therapies in the Research Pipeline Long-Term Efficacy and Safety of Approved DMTs Comparative Analyses of Approved DMTs New Diagnostic Testing Various Strategies for Wellness and Symptom Management, Physical Activity and Exercise, Vitamin D, and Reproductive-Health Topics Hot Topics in MS: Stem Cells, Lipoic Acid, Diet and MS, Obesity and MS, Gut […]

Read News Article

FDA Approves Gilenya® for Pediatric MS

On May 11, 2018, Novartis announced that Gilenya® (fingolimod) was approved by the United States Food and Drug Administration (FDA) for the treatment of children and adolescents, ages 10 through 17, with relapsing multiple sclerosis (MS). This is the first disease-modifying therapy (DMT) to be approved for this form of the disease in this age […]

Read News Article